The abstract is read at the publisher; the summary is JClub's.
In the Stockholm Study, interpretable multimodal networks distinguished hepatic molecular signatures for simvastatin, ezetimibe, and their combination, while placebo produced a less multimodal, more fragmented network.
- Why it matters: Multimodal clinical–omics integration could clarify hepatic mechanisms of lipid-lowering therapies, but interpretable methods for heterogeneous data are limited.
- What they did: Patients scheduled for cholecystectomy were randomized for 4 weeks to simvastatin, ezetimibe, combination, or placebo; liver transcriptomics and DNA methylation were integrated with plasma/bile biochemistry on the human protein-protein interactome to build treatment-specific IMNs.
- The result: IMNs highlighted apolipoprotein-centered modules and predicted effects on APOA2, PPARA, and PTPRS, with experimental support in SOAT2-only-HepG2 cells including APOA2 induction and ezetimibe-associated PTPRS upregulation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.